Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

ProteinE (1)

ProteinS (1)


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 2 records in total 2
    records per page




    Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 HGNC Expression and Attenuates SARS-CoV-2 Infection MESHD in vitro

    Authors: Dean Gilham; Audrey L Smith; Li Fu; Dalia Y Moore; Abenaya Muralidharan; St. Patrick M Reid; Stephanie C Stotz; Jan O Johansson; Michael Sweeney; Norman CW Wong; Ewelina Kulikowski; Dalia El-Gamal

    doi:10.1101/2021.03.10.432949 Date: 2021-03-11 Source: bioRxiv

    Effective therapeutics are urgently needed to counter infection and improve outcomes for patients suffering from COVID-19 MESHD and to combat this pandemic. Manipulation of epigenetic machinery to influence viral infectivity of host cells is a relatively unexplored area. The bromodomain and extraterminal ( BET HGNC) family of epigenetic readers have been reported to modulate SARS-CoV-2 infection MESHD. Herein, we demonstrate apabetalone, the most clinical advanced BET HGNC inhibitor, downregulates expression of cell surface receptors involved in SARS-CoV-2 entry MESHD, including angiotensin-converting enzyme 2 HGNC ( ACE2 HGNC) and dipeptidyl-peptidase 4 HGNC ( DPP4 HGNC or CD26 HGNC) in SARS-CoV-2 permissive cells. Moreover, we show that apabetalone inhibits SARS-CoV-2 infection MESHD in vitro to levels comparable to antiviral agents. Taken together, our study supports further evaluation of apabetalone to treat COVID-19 MESHD, either alone or in combination with emerging therapeutics.

    A proteomic model of SARS-COV2 infection by comparing the interactomes of BRD4 HGNC with BET HGNC-inhibition and SARS-COV2 viral proteins – implications for re-purposing approved drugs or ubiquitin-mediated degradation of select candidates

    Authors: GIRISH NALLUR

    doi:10.21203/rs.3.rs-24573/v1 Date: 2020-04-22 Source: ResearchSquare

    The novel coronavirus SARS-CoV-2, the causative agent of COVID-19 MESHD respiratory disease MESHD, has infected 2,029,930 people worldwide and caused 136,320 deaths. Consequently, the hunt for drugs showing efficacy against this deadly disease, or vaccines for prevention, are being intensely investigated. Unfortunately, there is a scarcity of research data on the molecular mechanisms of SARS-CoV-2 infection MESHD for quickly finding effective therapies, or repurposing existing drugs approved by the US FDA. This report models existing knowledge of SARS-COV2 viral proteins and the cellular proteins they interact with by comparisons with BRD4 HGNC interacting proteins identified from B cells, with or without BET HGNC inhibition. The E protein PROTEIN of SARS-COV2 interacts with BRD4 HGNC, and the Spike (S) protein PROTEIN with CANX HGNC. Extensive similarities were observed with published cellular interactants of 13 SARS-COV2 proteins resulting in 47 BRD4 HGNC-interacting protein candidates, with or without BET HGNC inhibition. 61 cellular protein targets and 132 FDA approved drugs which use these proteins as targets are proposed, which can be investigated for efficacy against SARS-COV2 infections MESHD. The implications to SARS-COV2 disease MESHD diagnosis, therapy and vaccine creation are discussed.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.